This study retrospectively investigated the association of targeted therapy with the outcomes of immunotherapy in advanced NSCLC patients with common EGFR sensitive mutation, and firstly identified a subgroup who could be most likely to benefit from IO combination treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.